Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?

Tirzepatide has produced greater average weight loss than semaglutide in clinical trials — roughly 15–22.5% of body weight in the SURMOUNT studies versus about 15% for semaglutide in the STEP series. The tradeoff: tirzepatide is a dual GIP/GLP-1 agonist, is typically priced higher, and some patients tolerate semaglutide's single-receptor profile better.

But they're not the same. One activates a single receptor. The other activates two. The clinical data shows a measurable difference in average weight loss outcomes. And depending on your health history, your budget, and what your physician recommends, one may make more sense for you than the other.

This article is a complete, honest comparison — built on peer-reviewed trial data from the SURMOUNT series (tirzepatide) and the STEP series (semaglutide). No hype. No oversimplification. Just what you need to have an informed conversation with a physician.

The Short Answer

Tirzepatide has produced greater average weight loss in clinical trials. That's the honest answer. But "greater on average" does not mean "better for every person." Semaglutide has a longer track record, broader prescribing experience, and for many patients, it produces results that are more than sufficient — with a cost and availability profile that may be more practical.

Both are excellent options. The goal of this article is to help you understand the differences clearly enough to have a real conversation with your physician about which makes sense for you specifically.

How Each One Works

Semaglutide: GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut naturally releases after eating. GLP-1 signals your brain that you're full, slows the rate at which your stomach empties, and supports healthier insulin response when blood sugar is elevated.

The result: reduced appetite, smaller portion sizes, fewer cravings. Many people describe it as turning down the volume on food noise — that background hum of hunger and craving that most diets can't silence through willpower alone.

Semaglutide received FDA approval for chronic weight management under the brand name Wegovy in June 2021, at a weekly dose of 2.4 mg. It had previously been approved for type 2 diabetes management at lower doses. For a deeper look at how the compounded version differs from the brand, see our honest guide to compounded semaglutide.

Tirzepatide: Dual GIP/GLP-1 Receptor Agonist

Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single molecule that activates two separate hormone pathways simultaneously. The GLP-1 component works the same way as semaglutide. The GIP component — glucose-dependent insulinotropic polypeptide — adds a second mechanism that appears to influence fat storage, energy metabolism, and how the body responds to the GLP-1 signal itself.

Research suggests that activating the GIP receptor alongside the GLP-1 receptor may amplify the overall metabolic effect, which is reflected in the trial data. Whether GIP's contribution is primarily additive or synergistic with GLP-1 is still an active area of research.

Tirzepatide received FDA approval for chronic weight management under the brand name Zepbound in November 2023. It had been approved for type 2 diabetes under the brand name Mounjaro in May 2022.

What the Clinical Trials Actually Show

Semaglutide: The STEP Trials

Semaglutide for weight management was studied in the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program, a series of large, randomized, placebo-controlled studies.

The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity or overweight and at least one weight-related condition. Participants received semaglutide 2.4 mg once weekly or placebo, alongside lifestyle counseling. Key findings after 68 weeks:

• Participants using semaglutide achieved a mean body weight reduction of approximately 14.9%
• Participants using placebo achieved a mean body weight reduction of approximately 2.4%
• Approximately 86% of semaglutide participants achieved at least 5% weight loss
• Approximately 69% achieved at least 10% weight loss
• Approximately 50% achieved at least 15% weight loss

The STEP 2 trial examined semaglutide in adults with type 2 diabetes and showed a mean weight reduction of approximately 9.6% at 68 weeks. The STEP 3 trial, which added intensive behavioral intervention, showed an average of approximately 16% weight reduction — demonstrating that lifestyle modifications amplify GLP-1 outcomes.

Tirzepatide: The SURMOUNT Trials

Tirzepatide for weight management was studied in the SURMOUNT clinical trial program, similarly large and placebo-controlled.

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity or overweight with at least one weight-related condition (excluding diabetes). Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo. Key findings after 72 weeks:

• Participants on 5 mg tirzepatide achieved a mean weight reduction of approximately 15.0%
• Participants on 10 mg tirzepatide achieved a mean weight reduction of approximately 19.5%
• Participants on 15 mg tirzepatide achieved a mean weight reduction of approximately 20.9%
• Placebo participants achieved a mean reduction of approximately 3.1%
• At the 15 mg dose, approximately 57% of participants achieved at least 20% weight loss

The SURMOUNT-2 trial examined tirzepatide in adults with type 2 diabetes, showing mean weight reductions of approximately 13.4% (10 mg) and 15.7% (15 mg). These are meaningful results even in a population where GLP-1 response is often attenuated by the metabolic effects of diabetes.

What the Numbers Actually Mean

A direct head-to-head trial between tirzepatide and semaglutide specifically for obesity (the SURMOUNT-5 trial) has reported results showing tirzepatide producing greater average weight loss at 72 weeks. Published data from this trial showed tirzepatide participants achieving a mean weight reduction of approximately 20.2% compared to approximately 13.7% for semaglutide — a statistically significant difference.

However, clinical trial averages tell you what happens in a large, controlled population. Your individual response depends on your metabolism, your adherence to lifestyle modifications, your dose tolerance, and a range of other factors that averages can't predict. Some people respond exceptionally well to semaglutide. Others find tirzepatide's tolerability more manageable. Physician guidance matters here.

Side-by-Side Comparison

Side Effects and Tolerability

Both medications share a nearly identical side effect profile. This isn't a coincidence — it's a direct result of their shared GLP-1 mechanism. The most commonly reported side effects for both tirzepatide and semaglutide are:

• Nausea — the most frequent complaint, especially during dose escalation. For most patients, it diminishes over several weeks as the body adjusts.
• Diarrhea or constipation — GI motility changes are common with both medications. Staying hydrated and eating smaller, lower-fat meals can help.
• Vomiting — more likely if doses are escalated too quickly or if eating habits don't adjust to reduced stomach capacity.
• Abdominal discomfort — bloating and cramping are reported by a subset of users with both medications.
• Fatigue — some users report low energy in the early weeks, particularly during caloric reduction.

Less common but more serious risks — applicable to both — include pancreatitis, gallbladder disease, and potential kidney effects from dehydration related to GI side effects. Neither medication is recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Does One Tolerate Better Than the Other?

In the SURMOUNT-5 head-to-head trial, overall gastrointestinal tolerability between tirzepatide and semaglutide was broadly comparable. Discontinuation rates due to adverse events were similar. Individual experiences, however, vary considerably — some patients who struggled with nausea on semaglutide report better tolerability with tirzepatide, and vice versa.

The most reliable predictor of tolerability is the dose escalation schedule. A slow, gradual ramp — starting at the lowest effective dose and increasing only when the body has adjusted — reduces GI side effects significantly regardless of which medication you're on. This is a core feature of any well-designed physician-directed protocol.

Cost and Accessibility

Brand-Name Pricing

Without insurance, brand-name GLP-1 medications are expensive. Zepbound (tirzepatide) and Wegovy (semaglutide) both carry list prices in the range of $1,000–$1,500 per month depending on dose. Insurance coverage varies significantly. Many plans require prior authorization, BMI and comorbidity thresholds, and documentation of prior weight-loss attempts — adding weeks of delay and uncertainty.

Compounded Alternatives

Licensed US compounding pharmacies have made GLP-1 therapy accessible at a fraction of brand-name pricing. Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredients, prepared to order by licensed pharmacists in state-regulated facilities. Physician-directed programs that source through regulated pharmacies typically offer these medications at $200–$600 per month, depending on dose and program structure. Our full cost breakdown for compounded tirzepatide in 2026 walks through what drives the price at each dose level.

The regulatory environment for compounded GLP-1 medications has shifted over time and continues to evolve. FDA shortage designations affect which compounds can be legally prepared — our plain-language walkthrough of the 2026 FDA GLP-1 compounding rules explains where the legal lines currently sit. A physician-directed program keeps your protocol aligned with current requirements — so you're not navigating this alone.

What You're Actually Paying For

Cost comparisons should account for what's included. The lowest price isn't always the best value. A clinically sound program should include:

• Licensed physician evaluation and prescription
• Medication sourced from a licensed, regulated compounding pharmacy
• Structured dose-escalation guidance
• Ongoing provider access for adjustments and questions
• Direct-to-door delivery with proper cold-chain handling

Which One Might Be Right for You

This is ultimately a question for your physician. But here's an honest framework for thinking about it.

Tirzepatide may make sense if:

• You have a significant amount of weight to lose and want to maximize average outcomes based on trial data
• You've previously tried semaglutide and found your response plateaued at a level that didn't meet your goals
• Your physician has assessed your metabolic profile and believes the dual-agonist mechanism is a good fit
• Access and cost are manageable within your situation

Semaglutide may make sense if:

• You're newer to GLP-1 therapy and want to start with the medication that has the longer clinical track record and broader prescribing experience
• Your weight loss goal is in the range of 10–15% body weight, which semaglutide has demonstrated in clinical trials
• Semaglutide is more accessible or better-priced within your physician-directed program
• Your physician recommends it based on your health history, current medications, or other clinical factors

The Honest Bottom Line

On average, tirzepatide produces greater weight loss. That's what the data says. But averages describe populations, not individuals. A person who responds well to semaglutide may lose more weight than a person who responds poorly to tirzepatide — and there's no way to predict individual response perfectly in advance.

What matters most is that you start. Both medications have robust clinical evidence behind them. Both are significantly more effective than any diet alone for most people who use them with physician oversight. The gap between the two medications is far smaller than the gap between either medication and doing nothing.

Work with a physician. Start with the medication that's appropriate for your situation. Monitor your response. Adjust if needed.

Frequently Asked Questions

Is tirzepatide stronger than semaglutide for weight loss?

Clinical trial data suggests tirzepatide may produce greater average weight loss. In the SURMOUNT-1 trial, participants on the highest dose (15 mg) achieved an average of approximately 20.9% body weight reduction over 72 weeks. In the STEP 1 trial, semaglutide 2.4 mg participants averaged approximately 14.9% reduction over 68 weeks. However, individual response varies significantly, and both medications are considered highly effective. The "stronger" choice depends on your health history, tolerability, and your physician's assessment.

What is the difference between tirzepatide and semaglutide?

The primary difference is the mechanism of action. Semaglutide is a GLP-1 receptor agonist — it activates one hormone pathway. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two pathways simultaneously. The GIP component in tirzepatide may contribute to additional effects on fat storage and energy metabolism. Both are once-weekly subcutaneous injections, and both require a physician prescription.

Which has more side effects: tirzepatide or semaglutide?

Both share a similar gastrointestinal side effect profile — nausea, diarrhea, constipation, and vomiting are the most commonly reported for each. In head-to-head analyses, tirzepatide and semaglutide show broadly comparable tolerability, though individual responses vary. Physician-directed dose escalation — starting low and increasing gradually — is the primary strategy for managing side effects with either medication.

Can I switch from semaglutide to tirzepatide?

Some patients do transition between GLP-1 medications, but this should only happen under physician supervision. Your provider will assess your response, weight loss progress, side effect history, and current dose before recommending a switch. A transition protocol typically includes a careful dose adjustment and a new escalation schedule.

Is compounded tirzepatide or semaglutide available?

Compounded versions of both medications have been available through licensed US compounding pharmacies. Availability and regulatory status can shift based on FDA shortage designations and policy updates. A physician-directed program like Nuvari will source from regulated pharmacies and keep your protocol aligned with current requirements — so you don't have to navigate the regulatory landscape on your own.